Table 1

Therapeutic effect by RT and immunotherapy combinations. Cox regression analysis comparing all treatments to RT+L19–IL2 or RT monotherapy used as control. HR <1 indicates superior treatment compared with RT+L19–IL2 or RT

TumorComparison of multiple treatments with the control treatment RT +L19–IL2
HR(95% CI)
(P value)
–RT+anti-CTLA-4RT+L19–IL2+anti-CTLA-4RT+anti-PD-L1RT+L19–IL2+anti-PD-L1RT+anti-PD-1RT+L19–IL2+anti-PD-1
LLC–1.71
(0.6 to 4.88)
(0.32)		0.49
(0.16 to 1.48)
(0.2)		3.58
(1.19 to 10.73)
(0.022)		0.28
(0.08 to 0.92)
(0.035)		1.65
(0.57 to 4.72)
(0.35)		0.46
(0.14 to 1.47)
(0.19)
CT26–1.44
(0.53 to 3.9)
(0.48)		0.52
(0.17 to 1.57)
(0.24)		1.23
(0.43 to 3.49)
(0.7)		0.92
(0.33 to 2.52)
(0.88)		2.77
(0.72 to 10.62)
(0.14)		0.43
(0.1 to 1.78)
(0.25)
C51–7.31
(2.39 to 22.29)
(<0.0005)		0.73
(0.24 to 2.18)
(0.57)		9.15
(2.81 to 29.77)
(<0.0005)		0.9
(0.31 to 2.58)
(0.84)		9.95
(2.92 to 33.83)
(<0.0005)		0.69
(0.23 to 2.02)
(0.49)
Comparison of multiple treatments with the control treatment RT
HR (95% CI)
(P value)
 RT+L19–IL2RT+anti-CTLA-4RT+L19–IL2+anti-CTLA-4RT+anti-PD-L1RT+L19–IL2+anti-PD-L1RT+anti-PD-1RT+L19–IL2+anti-PD-1
LLC0.17
(0.05 to 0.54)
(0.003)		0.29
(0.1 to 0.84)
(0.022)		0.08
(0.02 to 0.28)
(<0.0005)		0.62
(0.22 to 1.72)
(0.35)		0.05
(0.01 to 0.18)
(<0.0005)		0.28
(0.09 to 0.82)
(0.02)		0.08
(0.02 to 0.28)
(<0.0005)
CT260.14
(0.04 to 0.44)
(0.001)		0.21
(0.07 to 0.62)
(0.004)		0.07
(0.02 to 0.26)
(<0.0005)		0.18
(0.05 to 0.55)
(0.002)		0.13
(0.04 to 0.41)
(<0.0005)		0.48
(0.13 to 1.71)
(0.26)		0.074
(0.01 to 0.39)
(0.002)
C510.07
(0.01 to 0.25)
(<0.0005)		0.51
(0.17 to 1.44)
(0.2)		0.05
(0.01 to 0.19)
(<0.0005)		0.63
(0.22 to 1.8)
(0.39)		0.062
(0.01 to 0.22)
(<0.0005)		1.98
(0.65 to 5.97)
(0.2)		0.14
(0.03 to 0.52)
(0.003)

  • Significant HR and two-sided p values are shown in bold.

  • LLC, Lewis lung carcinoma; RT, radiotherapy.